Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -160.64% is 55% below its 2-year average of -103.44%, near the low end of its 2-year range (-160.64%–-52.52%).
24.63% below its 12-month average of -128.90%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -40.29%.
RETURN ON ASSETS (ROA)
-160.64%
RETURN ON ASSETS (ROA) AVG TTM
-128.90%
RETURN ON ASSETS (ROA) AVG 3Y
N/A
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-24.63%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.94%
median of 845 covered companies
CURRENT VS SECTOR MEDIAN
-402.94%
vs the sector median at left
CapsoVision, Inc.
Market Cap
$324.76M
Return on Assets (ROA)
-160.64%
TTM Avg
-128.90%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$322.85M
Return on Assets (ROA)
-70.63%
TTM Avg
-82.15%
3Y Avg
-59.06%
5Y Avg
-50.33%
Market Cap
$321.85M
Return on Assets (ROA)
-46.30%
TTM Avg
-31.23%
3Y Avg
-20.32%
5Y Avg
-24.57%
Market Cap
$320.29M
Return on Assets (ROA)
-39.85%
TTM Avg
-37.20%
3Y Avg
-38.95%
5Y Avg
-33.46%
Market Cap
$319.65M
Return on Assets (ROA)
-90.17%
TTM Avg
-81.88%
3Y Avg
-55.65%
5Y Avg
-44.24%
Market Cap
$318.98M
Return on Assets (ROA)
53.28%
TTM Avg
-50.19%
3Y Avg
-57.97%
5Y Avg
-53.56%
Market Cap
$313.46M
Return on Assets (ROA)
-28.22%
TTM Avg
-29.68%
3Y Avg
-31.08%
5Y Avg
-26.24%
Market Cap
$302.32M
Return on Assets (ROA)
-24.94%
TTM Avg
-31.51%
3Y Avg
-135.72%
5Y Avg
-152.11%
Market Cap
$301.90M
Return on Assets (ROA)
-96.57%
TTM Avg
-96.57%
3Y Avg
-96.57%
5Y Avg
-96.57%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CapsoVision, Inc. (CV) | $324.76M | -160.64% | -128.90% | N/A | N/A |
| Cabaletta Bio, Inc. (CABA)vs › | $322.85M | -70.63% | -82.15% | -59.06% | -50.33% |
| Sanara MedTech Inc. (SMTI)vs › | $321.85M | -46.30% | -31.23% | -20.32% | -24.57% |
| ClearPoint Neuro, Inc. (CLPT)vs › | $320.29M | -39.85% | -37.20% | -38.95% | -33.46% |
| Avita Medical Inc. (RCEL)vs › | $319.65M | -90.17% | -81.88% | -55.65% | -44.24% |
| Agenus Inc. (AGEN)vs › | $318.98M | 53.28% | -50.19% | -57.97% | -53.56% |
| C4 Therapeutics, Inc. (CCCC)vs › | $313.46M | -28.22% | -29.68% | -31.08% | -26.24% |
| Benitec Biopharma Inc. (BNTC)vs › | $302.32M | -24.94% | -31.51% | -135.72% | -152.11% |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $301.90M | -96.57% | -96.57% | -96.57% | -96.57% |
| Relmada Therapeutics, Inc. (RLMD)vs › | $348.27M | -28.27% | -117.81% | -109.90% | -91.03% |
ROA
-160.6%
ROE
-226.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -139.37% |
| 2024-12-31 | -118.42% |
| 2023-12-31 | -52.52% |
